Corcept Therapeutics Incorporated
CORT
$73.06
-$3.59-4.68%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.79% | 23.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.79% | 23.67% | |||
| Cost of Revenue | 33.88% | 42.86% | |||
| Gross Profit | 6.31% | 23.37% | |||
| SG&A Expenses | 19.38% | 14.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.68% | 9.07% | |||
| Operating Income | -61.69% | 680.88% | |||
| Income Before Tax | -51.90% | 229.51% | |||
| Income Tax Expenses | -28.00% | 68.37% | |||
| Earnings from Continuing Operations | -44.04% | 71.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -44.04% | 71.07% | |||
| EBIT | -61.69% | 680.88% | |||
| EBITDA | -61.03% | 628.48% | |||
| EPS Basic | -43.74% | 70.55% | |||
| Normalized Basic EPS | -51.66% | 229.81% | |||
| EPS Diluted | -44.83% | 70.59% | |||
| Normalized Diluted EPS | -51.46% | 227.49% | |||
| Average Basic Shares Outstanding | -0.54% | 0.00% | |||
| Average Diluted Shares Outstanding | -0.87% | 0.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||